Blog

  • ACCESS Newswire Reports Third Quarter 2025 Results

    ACCESS Newswire Reports Third Quarter 2025 Results

     Increased ARR Leads to Higher Revenue and EBITDA

    • Q3 2025 revenue grew modestly to $5.7M compared to $5.6M in Q2 2025 and Q3 2024

    • Q3 Adjusted EBITDA increased 71% to $933,000 compared to $546,000 in Q3 2024

    • Gross margin percentage remained strong at 75%

    RALEIGH, NC / ACCESS Newswire / November 11, 2025 / ACCESS Newswire Inc. (NYSE American:ACCS), a leading communications company, today reported its operating results for the three and nine months ended September 30, 2025.

    “Q3 was another positive quarter for ACCESS Newswire, marked by operational discipline, continued customer growth and increased Adjusted EBITDA,” said Brian R. Balbirnie, ACCESS Newswire’s Founder and Chief Executive Officer. “We have clear visibility into the opportunities ahead, and we are confident that the steps we are taking now will deliver long-term value for our shareholders.”

    Mr. Balbirnie continued, “ACCESS Newswire is entering a pivotal period of product advancement. As we move into the final quarter of the year, we remain focused on driving growth through continued product innovation and operational efficiency. With a broad and expanding set of communications solutions, we believe we are well-positioned to capture additional market-share in the evolving communications landscape. The product enhancements we plan to introduce before year-end are designed to further enhance the customer experience and support sustained top-line growth.”

    Third Quarter 2025 Highlights:

    • Revenue – Total revenue was $5.7M, a 2% increase from $5.6M in Q3 2024 and Q2 2025. The increase in revenue during the quarter is due to an increase in core press release revenue of approximately 7% and 4% as compared to the same periods of the prior year and prior quarter, respectively. The increase in revenue is primarily attributable to increases in volume during these periods.

    • Gross Margin – Gross margin for Q3 2025 was $4.3M, or 75% of revenue, compared to $4.2M, also 75% of revenue, during Q3 2024 and $4.3M, or 76% of revenue in Q2 2025. Gross margin was impacted by increased distribution costs as we continue to invest in our distribution partners, however, this was partially offset by lower employee costs due to optimization of our operational teams.

    • Operating Loss -Operating loss was $184,000 for Q3 2025, as compared to $604,000 during Q3 2024. Operating expenses decreased $380,000, or 8%, to $4.5 million. The decrease was primarily due to a reduction in general and administrative expenses due to decreases in headcount, provision for credit losses, as well as indirect costs associated with the Compliance business.

    • Loss from continuing operations – On a GAAP basis, net loss from continuing operations was $45,000, or $0.01 per diluted share, for Q3 2025, compared to $870,000, or $0.23 per diluted share, for Q3 2024. In addition to our lower operating loss, the decrease in loss from continuing operations is due to lower interest expense due to our restructured debt, increased interest income as well as lower loss on change in fair value of our interest rate swap.

    • Non-GAAP Measures -Q3 2025 EBITDA was $537,000, or 9%, compared to $(212,000), or (4)%, during Q3 2024. Adjusted EBITDA was $933,000, or 16% of revenue, for Q3 2025 compared to $546,000, or 10% of revenue, for Q3 2024. Non-GAAP net income for Q3 2025 was $760,000, or $0.20 per diluted share, compared to $187,000, or $0.05 per diluted share, during Q3 2024. Adjusted free-cash flow was $(418,000) for Q3 2025 compared to $1.4M for Q3 2024. Q3 2025 included over $1.1M of tax payments related to gain on sale of the compliance business.

    Year To Date Q3 2025 Highlights:

    • Revenue – Total revenue was $16.8M, a 2% decrease from $17.2M during the first nine months of 2024. The decrease was primarily due to declines in revenue across our product lines, however, core press release revenue increased 1%.

    • Gross Margin – Gross margin for the first nine months of 2025 was $12.8M, or 76% of revenue, compared to $13.1M, also 76% of revenue, during the first nine months of 2024. As noted for the quarter, gross margin was impacted by increased distribution costs as we continue to invest in our distribution partners, however, this was partially offset by lower employee costs due to optimization of our operational teams.

    • Operating Loss -Operating loss was $1.1M, for the first nine months of 2025, as compared to $2.0M during the first nine months of 2024. Operating expenses decreased over $1.1M, or 7%, to $13.9M. This decrease was primarily due to a reduction in headcount and operational efficiencies throughout the organization.

    • Loss from continuing operations – On a GAAP basis, net loss from continuing operations was $1.0M, or $0.26 per diluted share during the first nine months of 2025, compared to $2.3M, or $0.61 per diluted share during the first nine months of 2024.

    • Non-GAAP Measures -EBITDA for the first nine months of 2025 was $1.0M, or 6%, compared to $70,000 during the first nine months of 2024. Adjusted EBITDA was $2.3M, or 14% of revenue, for the first nine months of 2025 compared to $961,000, or 6% of revenue, for the first nine months of 2024. Non-GAAP net income for the first nine months of 2025 was $1.5M, or $0.39 per diluted share, compared to $(78,000), or $(0.02) per diluted share, during the first nine months of 2024. Adjusted free-cash flow was $799,000 for the first nine months of 2025 compared to $1.9M for first nine months of 2024. Adjusted free-cash flow for the first nine months of 2025 included $1.5M of tax payments primarily related to gain on sale of the compliance business.

    Key Performance Indicators:

    • As of September 30, 2025, we had 12,445 customers who had an active contract during the past twelve months.

    • Subscription customers increased during the quarter to 972.

    • Average ARR for subscriptions per customer at the end of the quarter was $11,651, up from $10,189 as of September 30, 2024.

    Non-GAAP Financial Measures

    The non-GAAP adjustments referenced below and herein relate to the exclusion of stock-based compensation, amortization of acquisition-related intangible assets. and other expenses the Company believes to be non-recurring. A reconciliation of GAAP to non-GAAP historical financial measures has been provided in the tables at the end of this press release.

    Management believes that the use of EBITDA from continuing operations, Adjusted EBITDA from continuing operations, non-GAAP net income (loss) from continuing operations, non-GAAP net income (loss) from continuing operations per share, free cash flow and adjusted free cash flow is helpful to its investors. These measures, which are referred to as non-GAAP financial measures, are not prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Our management uses these non-GAAP financial measures as tools for financial and operational decision making and for evaluating our own operating results over different periods of time.

    EBITDA from continuing operations is calculated by excluding depreciation and amortization, interest expense, net, and income taxes from the loss from continuing operations. Adjusted EBITDA also excludes certain other expenses which the Company believes to be non-recurring as well as the gain or loss on the change in fair value of our interest rate swap. Non-GAAP net income (loss) from continuing operations is calculated by excluding stock-based compensation expense and amortization expense for acquisition-related intangible assets from loss from continuing operations and certain other adjustments noted in the tables below. Non-GAAP net income (loss) from continuing operations per share is calculated by dividing non-GAAP net income (loss) from continuing operations by the weighted-average diluted shares outstanding as presented in the calculation of GAAP net income (loss) from continuing operations per share. Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, management believes that providing non-GAAP financial measures that exclude stock-based compensation expense allows for more meaningful comparisons between its operating results from period to period. For business combinations, management generally allocates a portion of the purchase price to intangible assets. The amount of the allocation is based on estimates and assumptions made by management and is subject to amortization. The amount of purchase price allocated to intangible assets and the term of its related amortization can vary significantly and are unique to each acquisition and thus management does not believe they are reflective of ongoing operations.

    Free cash flow, a non-GAAP measure, represents cash flow from operating activities less purchase of property and equipment and capitalized software. Adjusted free cash flow also deducts certain cash payments which the Company believe to be non-recurring in nature. Management considers free cash flow and adjusted free cash flow to be liquidity measures that provide useful information to investors about the amount of cash generated or used by the business.

    Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in the industry may calculate non-GAAP financial results differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on our reported financial results.

    The presentation of non-GAAP financial information below and herein are not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Investors should review the reconciliation of non-GAAP financial measures to the comparable GAAP financial measures included below and not rely on any single financial measure to evaluate our business.

    RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES
    ($ in ‘000’s, except per share amounts)
    CALCULATION OF EBITDA & ADJUSTED EBITDA

    Three Months Ended
    September 30,

    2025

    2024

    Amount

    Amount
    Net loss from continuing operations:

    $

    (45

    )

    $

    (870

    )
    Adjustments:
    Depreciation and amortization

    722

    735
    Interest expense, net

    (207

    )

    270
    Income tax expense (benefit)

    67

    (347

    )
    EBITDA from continuing operations

    537

    (212

    )
    Acquisition and/or integration costs (1)

    42

    43
    Other non-recurring expenses (2)

    174

    468
    Stock-based compensation expense (3)

    180

    247
    Adjusted EBITDA from continuing operations:

    $

    933

    $

    546

    Nine Months Ended
    September 30,

    2025

    2024

    Amount

    Amount
    Net loss from continuing operations:

    $

    (1,049

    )

    $

    (2,336

    )
    Adjustments:
    Depreciation and amortization

    2,203

    2,191
    Interest (income) expense, net

    (14

    )

    857
    Income tax expense (benefit)

    (127

    )

    (642

    )
    EBITDA from continuing operations

    1,013

    70
    Acquisition and/or integration costs (1)

    243

    150
    Other non-recurring expenses (2)

    505

    336
    Stock-based compensation expense (3)

    572

    405
    Adjusted EBITDA from continuing operations:

    $

    2,333

    $

    961

    (1)

    This adjustment gives effect to one-time corporate projects, including acquisition, divestiture and integration related expenses, incurred during the periods.

    (2)

    For the three months ended September 30, 2025, this adjustment gives effect to the loss on the change in fair value of our interest rate swap of $2,000 and non-recurring fees of $172,000. For the nine months ended September 30, 2025, this adjustment gives effect to the loss on the change in fair value of our interest rate swap of $80,000, as well as corporate re-brand costs of $132,000 and non-recurring fees of $293,000. For the three and nine months ended September 30, 2024, this adjustment gives effect to a loss recorded on the change in fair value of our interest rate swap of $343,000 and $124,000, respectively, as well as one-time accounting fees, termination benefits and other non-recurring or unusual expenses of $125,000 and $212,000, respectively.

    (3)

    The adjustments represent stock-based compensation expense from continuing operations related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects.

    CALCULATION OF NON-GAAP NET INCOME (LOSS)

    Three Months Ended
    September 30,

    2025

    2024

    Amount
    Per diluted
    share

    Amount
    Per diluted
    share
    Net loss from continuing operations:

    $

    (45

    )

    $

    (0.01

    )

    $

    (870

    )

    $

    (0.23

    )
    Adjustments:
    Amortization of intangible assets(1)

    622

    0.16

    639

    0.17
    Stock-based compensation expense(2)

    180

    0.05

    247

    0.06
    Other unusual items(3)

    216

    0.06

    511

    0.13
    Discrete items impacting income tax expense(4)

    –

    –

    (47

    )

    (0.01

    )
    Tax impact of adjustments(5)

    (213

    )

    (0.06

    )

    (293

    )

    (0.07

    )
    Non-GAAP net income from continuing operations:

    $

    760

    0.20

    $

    187

    $

    0.05
    Weighted average number of common shares outstanding – diluted

    3,870

    3,835

    Nine Months Ended
    September 30,

    2025

    2024

    Amount
    Per diluted
    share

    Amount
    Per diluted
    share
    Net loss from continuing operations:

    $

    (1,049

    )

    $

    (0.27

    )

    $

    (2,336

    )

    $

    (0.61

    )
    Adjustments:
    Amortization of intangible assets(1)

    1,882

    0.49

    1,919

    0.50
    Stock-based compensation expense(2)

    572

    0.14

    405

    0.11
    Other unusual items(3)

    748

    0.19

    486

    0.12
    Discrete items impacting income tax expense(4)

    41

    0.01

    38

    0.01
    Tax impact of adjustments(5)

    (672

    )

    (0.17

    )

    (590

    )

    (0.15

    )
    Non-GAAP net income (loss) from continuing operations:

    $

    1,522

    0.39

    $

    (78

    )

    $

    (0.02

    )
    Weighted average number of common shares outstanding – diluted

    3,857

    3,826

    (1)

    The adjustments represent the amortization of intangible assets related to acquired assets and companies.

    (2)

    The adjustments represent stock-based compensation expense from continuing operations related to awards of stock options, restricted stock units, or common stock in exchange for services. Although we expect to continue to award stock in exchange for services, the amount of stock-based compensation is excluded as it is subject to change as a result of one-time or non-recurring projects.

    (3)

    For the three months ended September 30, 2025, this adjustment gives effect to the loss on the change in fair value of our interest rate swap of $2,000 and non-recurring fees, including acquisition, integration and divestiture costs of $214,000. For the nine months ended September 30, 2025, this adjustment gives effect to the loss on the change in fair value of our interest rate swap of $80,000, as well as corporate re-brand costs of $132,000 and non-recurring fees, including acquisition, integration and divestiture costs of $536,000. For the three and nine months ended September 30, 2024, this adjustment gives effect to a loss recorded on the change in fair value of our interest rate swap of $343,000 and $124,000, respectively, as well as, one-time accounting fees, termination benefits and other non-recurring or unusual expenses, including acquisition and integration expenses of $168,000 and $362,000, respectively.

    (4)

    This adjustment gives effect to discrete items that impact income tax expense. For the three and nine months ended September 30, 2025 and 2024, this relates to additional expense associated with vesting of stock-based compensation awards.

    (5)

    This adjustment gives effect to the tax impact of all non-GAAP adjustments at the current Federal tax rate of 21%.

    CALCULATION OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW

    Three Months Ended
    September 30,

    2025

    2024
    Net cash provided by operating activities of continuing operations (GAAP)

    $

    (582

    )

    $

    1,498
    Payments for purchase of fixed assets and capitalized software

    (8

    )

    (140

    )
    Free cash flow from continuing operations (Non-GAAP)

    (590

    )

    1,358
    Cash paid for acquisition and integration related items (1)

    –

    –
    Cash paid for other unusual items (2)

    172

    11
    Adjusted free cash flow from continuing operations (Non-GAAP)

    $

    (418

    )

    $

    1,369

    Nine Months Ended
    September 30,

    2025

    2024
    Net cash provided by operating activities of continuing operations (GAAP)

    $

    300

    $

    2,294
    Payments for purchase of fixed assets and capitalized software

    (43

    )

    (556

    )
    Free cash flow from continuing operations (Non-GAAP)

    257

    1,738
    Cash paid for acquisition and integration related items (1)

    118

    23
    Cash paid for other unusual items (2)

    424

    99
    Adjusted free cash flow from continuing operations (Non-GAAP)

    $

    799

    $

    1,860

    (1)

    This adjustment gives effect to one-time corporate projects, including acquisition, divestiture and integration related expenses, paid during the periods.

    (2)

    For the three and nine months ended September 30, 2025, this relates to payments related to our corporate re-brand and other non-recurring fees. For the three and nine months ended September 30, 2024, this adjustment gives effect to one-time accounting fees, termination benefits and other non-recurring or unusual expenses.

    Conference Call Information

    To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

    Date:

    November 11, 2025

    Time:

    9:00 a.m. eastern time

    Toll & Toll Free:

    973-528-0011 | 888-506-0062

    Access Code:

    162391

    Live Webcast:

    https://www.webcaster5.com/Webcast/Page/2667/52262

    Conference Call Replay Information

    The replay will be available beginning approximately 1 hour after the completion of the live event.

    Toll & Toll Free:

    919-882-2331 | 877-481-4010

    Passcode:

    52262

    Webcast Replay & Transcript

    https://investors.accessnewswire.com/events-presentations

    About ACCESS Newswire Inc.

    We are ACCESS Newswire, a globally trusted Public Relations (PR) and Investor Relations (IR) solutions provider. With a focus on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands to connect with their audiences where it matters most. From startups and scale-ups to multi-billion-dollar global brands, we ensure your most important moments make an impact and resonate with your audiences. To learn more visit www.accessnewswire.com.

    Forward-Looking Statements

    Certain statements in this press release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the Company’s expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “commit,” “estimate,” “predict,” “potential,” “outlook,” “guidance,” “target,” “goal,” “project,” “continue to,” “confident,” or the negative of those terms or other comparable terminology. The forward-looking statements in this press release include, among other things, our confidence that the steps we are taking now will deliver long-term value for our shareholders, our belief we are well-positioned to capture additional market-share in the evolving communications landscape as a result of our broad and expanding set of communications solutions and our plan to introduce product enhancements before year-end which are designed to further enhance the customer experience and support sustained top-line growth.

    Please see the Company’s documents filed or to be filed with the Securities and Exchange Commission at www.sec.gov, including the Company’s Annual Reports filed on Form 10-K, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Reports on Form 10-Q, and any amendments thereto for a discussion of certain important risk factors that relate to forward-looking statements contained in this report. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For Further Information:

    ACCESS Newswire Inc.
    Brian R. Balbirnie
    (919)-481-4000
    brianb@accessnewswire.com

    Hayden IR
    Brett Maas
    (646)-536-7331
    brett@haydenir.com

    Hayden IR
    James Carbonara
    (646)-755-7412
    james@haydenir.com

    ACCESS NEWSWIRE INC. AND SUBSIDIARIES
    CONSOLIDATED BALANCE SHEETS
    (in thousands, except share and per share amounts)

    September 30,

    December 31,

    2025

    2024
    ASSETS

    (unaudited)
    Current assets:
    Cash and cash equivalents

    $

    3,261

    $

    4,103
    Accounts receivable (net of allowance for doubtful accounts of $1,661 and $1,059
    respectively

    4,137

    3,351
    Other current assets

    1,603

    1,234
    Current assets held for sale

    –

    1,338
    Total current assets

    9,001

    10,026
    Capitalized software (net of accumulated amortization of $3,854 and $3,644, respectively)

    747

    934
    Fixed assets (net of accumulated depreciation of $848 and $914, respectively)

    274

    365
    Right-of-use asset – leases

    575

    766
    Other long-term assets

    80

    158
    Goodwill

    19,043

    19,043
    Intangible assets (net of accumulated amortization of $8,906 and $7,024, respectively)

    10,094

    11,976
    Deferred tax asset

    4,236

    3,793
    Non-current assets held for sale

    –

    3,577
    Total assets

    $

    44,050

    $

    50,638
    LIABILITIES AND STOCKHOLDERS’ EQUITY
    Current liabilities:
    Accounts payable

    $

    1,354

    $

    1,423
    Accrued expenses

    2,038

    1,699
    Income taxes payable

    1,565

    56
    Current portion of long-term debt

    870

    4,000
    Deferred revenue

    5,020

    4,743
    Current liabilities held for sale

    –

    893
    Total current liabilities

    10,847

    12,814
    Long-term debt (net of debt discount of $57 and $70, respectively)

    1,899

    11,930
    Lease liabilities – long-term

    408

    668
    Deferred tax liability

    82

    –
    Other long-term liabilities

    20

    –
    Total liabilities

    13,256

    25,412
    Commitments and contingencies
    Stockholders’ equity:
    Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    –

    –
    Common stock $0.001 par value, 20,000,000 shares authorized, 3,868,826 and 3,838,743 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

    4

    4
    Additional paid-in capital

    24,909

    24,259
    Other accumulated comprehensive loss

    (127

    )

    (178

    )
    Retained earnings

    6,008

    1,141
    Total stockholders’ equity

    30,794

    25,226
    Total liabilities and stockholders’ equity

    $

    44,050

    $

    50,638

    ACCESS NEWSWIRE INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF OPERATIONS
    (UNAUDITED)
    (in thousands, except per share amounts)

    For the Three Months Ended

    For the Nine Months Ended

    September 30,

    September 30,

    September 30,

    September 30,

    2025

    2024

    2025

    2024
    Revenues

    $

    5,723

    $

    5,639

    $

    16,820

    $

    17,231
    Cost of revenues

    1,455

    1,411

    3,994

    4,172
    Gross profit

    4,268

    4,228

    12,826

    13,059
    Operating costs and expenses:
    General and administrative

    1,484

    1,893

    5,189

    5,374
    Sales and marketing expenses

    1,626

    1,592

    4,682

    5,606
    Product development

    684

    671

    2,072

    2,044
    Depreciation and amortization

    658

    676

    1,993

    2,032
    Total operating costs and expenses

    4,452

    4,832

    13,936

    15,056
    Operating loss

    (184

    )

    (604

    )

    (1,110

    )

    (1,997

    )
    Interest income (expense), net

    207

    (270

    )

    14

    (857

    )
    Other expense, net

    (1

    )

    (343

    )

    (80

    )

    (124

    )
    Income (loss) before taxes

    22

    (1,217

    )

    (1,176

    )

    (2,978

    )
    Income tax expense (benefit)

    67

    (347

    )

    (127

    )

    (642

    )
    Net loss from continuing operations

    (45

    )

    (870

    )

    (1,049

    )

    (2,336

    )
    Net income from discontinued operations, net of tax

    –

    404

    5,916

    1,738
    Net income (loss)

    $

    (45

    )

    $

    (466

    )

    $

    4,867

    $

    (598

    )
    Loss from continuing operations per share – basic

    $

    (0.01

    )

    $

    (0.23

    )

    $

    (0.27

    )

    $

    (0.61

    )
    Loss from continuing operations per share – fully diluted

    $

    (0.01

    )

    $

    (0.23

    )

    $

    (0.27

    )

    $

    (0.61

    )
    Income from discontinued operations per share – basic

    $

    0.00

    $

    0.11

    $

    1.53

    $

    0.45
    Income from discontinued operations per share – fully diluted

    $

    0.00

    $

    0.11

    $

    1.53

    $

    0.45
    Income (loss) per share – basic

    $

    (0.01

    )

    $

    (0.12

    )

    $

    1.26

    $

    (0.16

    )
    Income (loss) per share – fully diluted

    $

    (0.01

    )

    $

    (0.12

    )

    $

    1.26

    $

    (0.16

    )
    Weighted average number of common shares outstanding – basic

    3,869

    3,833

    3,856

    3,823
    Weighted average number of common shares outstanding – fully diluted

    3,870

    3,835

    3,857

    3,826

    ACCESS NEWSWIRE INC. AND SUBSIDIARIES
    CONSOLIDATED STATEMENTS OF CASH FLOWS
    (UNAUDITED)
    (in thousands)

    For the Nine Months Ended

    September 30,

    September 30,

    2025

    2024
    Cash flows from operating activities:
    Net income (loss)

    $

    4,867

    $

    (598

    )
    Adjustments to reconcile net income to net cash provided by operating activities:
    Gain on disposal of business

    (8,974

    )

    –
    Depreciation and amortization

    2,231

    2,317
    Provision for credit losses

    1,056

    906
    Deferred income taxes

    (360

    )

    (99

    )
    Change in fair value of interest rate swaps

    –

    124
    Stock-based compensation expense

    650

    468
    Non-cash interest adjustment on note payable

    13

    13
    Changes in operating assets and liabilities:
    Decrease (increase) in accounts receivable

    (1,056

    )

    (951

    )
    Decrease (increase) in other assets

    411

    78
    Increase (decrease) in accounts payable

    8

    113
    Increase (decrease) in income tax payable

    1,509

    2
    Increase (decrease) in accrued expenses

    (26

    )

    17
    Increase (decrease) in deferred revenue

    (29

    )

    (96

    )
    Net cash provided by operating activities

    300

    2,294
    Cash flows from investing activities:
    Proceeds from Sale of Compliance Business

    12,000

    –
    Capitalized software

    (23

    )

    (537

    )
    Purchase of fixed assets

    (20

    )

    (19

    )
    Net cash provided by (used in) investing activities

    11,957

    (556

    )
    Cash flows from financing activities:
    Payment of long-term debt

    (13,174

    )

    (3,333

    )
    Net cash used in financing activities

    (13,174

    )

    (3,333

    )
    Net change in cash and cash equivalents

    (917

    )

    (1,595

    )
    Cash and cash equivalents – beginning

    4,103

    5,714
    Currency translation adjustment

    75

    (33

    )
    Cash and cash equivalents – ending

    $

    3,261

    $

    4,086
    Supplemental disclosures:
    Cash paid for income taxes

    $

    1,519

    $

    170
    Cash paid for interest

    $

    368

    $

    1,093

    SOURCE: ACCESS Newswire Inc.

    View the original press release on ACCESS Newswire

  • Baton Rouge Defense Attorney Responds to Surge in Credit Card Abuse Cases Across Louisiana

    Baton Rouge Defense Attorney Responds to Surge in Credit Card Abuse Cases Across Louisiana

    November 10, 2025 – PRESSADVANTAGE –

    As federal authorities report a significant, continued surge in credit card fraud cases nationwide, veteran Baton Rouge criminal defense attorney David E. Stanley is cautioning Louisiana residents about the serious legal consequences of credit card abuse charges under Louisiana state law.

    According to recent data from the Federal Trade Commission’s Consumer Sentinel Network, credit card fraud remains the most common type of identity theft in America, showing a dramatic increase in reported cases compared to the same period last year, a trend consistent with the rise in financial fraud seen nationally. The surge has prompted heightened scrutiny from law enforcement agencies across Louisiana, leading to more arrests and prosecutions for violations of Louisiana Revised Statute 14:67.11, which specifically governs the unauthorized use of credit cards, a form of financial fraud distinct from general identity theft.

    “We’re seeing a significant uptick in clients facing credit card abuse charges, many of whom don’t fully understand how Louisiana law defines these offenses or the severity of the penalties they’re facing,” said David E. Stanley, who has practiced criminal defense in Baton Rouge since 1983. “These aren’t just minor offenses—Louisiana law classifies certain credit card fraud cases as felonies, carrying potential penalties of up to 10 years in prison and fines up to $5,000, depending on the total value of the property obtained and the facts of the case.”

    Under Louisiana law, unauthorized use of a credit card includes a wide range of conduct beyond simple theft. The statute criminalizes using someone else’s credit card information without authorization, making purchases with a revoked card, or even failing to deliver goods or services after processing a customer’s payment. Business owners and employees who misuse customer payment information during legitimate transactions can also face prosecution under these provisions.

    The recent surge in cases likely reflects both increased digital fraud and more proactive prosecution by district attorneys’ offices throughout the state. David E. Stanley noted that many individuals arrested for unauthorized use of a credit card may not have intended to commit fraud but made mistakes in business transactions or misunderstood their authorization to use another person’s payment information.

    The attorney emphasized that early intervention is crucial for anyone facing credit card abuse allegations. In Louisiana, prosecutors have discretion to pursue charges even when a complainant wishes to withdraw, because offenses such as unauthorized use of a credit card are considered crimes against the state rather than private disputes. The financial threshold for felony prosecution is also relatively low compared to other states.

    David E. Stanley’s defense approach focuses on evaluating evidence of intent, carefully investigating each case, and seeking favorable resolutions in accordance with Louisiana law. His four decades of experience in Louisiana courts provide clients with knowledge of local judicial procedures and relationships with prosecutors that can prove valuable during case resolution.

    The increase in credit card fraud cases has also resulted in more individuals being included in investigations, including those later determined to have no involvement. David E. Stanley noted that legitimate cardholders sometimes face accusations when family members or employees misuse their cards, or when data breaches expose their information to actual criminals.

    For Louisiana residents concerned about potential credit card abuse charges or currently under investigation, David E. Stanley offers consultations to review the specifics of each case and explain available legal options. His practice serves clients throughout Baton Rouge and surrounding Louisiana communities.

    For more information about legal representation in credit card or financial crime matters, visit davidstanleylaw.com or call (225) 926‑0200.

    About David E. Stanley, APLC

    David E. Stanley, APLC, has provided criminal defense representation in Baton Rouge, Louisiana, since 1983. The practice handles a wide range of criminal matters, including violent crimes, drug charges, sex crimes, vehicular homicide, DUI cases, and financial crimes such as credit card abuse. David E. Stanley takes a personalized approach to each case, focusing on understanding clients’ unique circumstances and building defense strategies tailored to their specific situations.

    ###

    For more information about David E. Stanley, APLC, contact the company here:

    David E. Stanley, APLC
    David E. Stanley
    225-926-0200
    david@destanleylaw.com
    1055 Laurel St #2, Baton Rouge, LA 70802, United States

  • Spanglish Movies Unveils “Sound of Freedom: Hidden War” Official Trailer, Building Buzz for November 14 Theatrical Release

    Miami, FL November 10, 2025 –(PR.com)– The production team behind Hidden War has unveiled the official trailer for the film, setting the stage for its nationwide theatrical debut on November 14, 2025.​

    The trailer can be viewed at: https://youtu.be/-yx7DdwRiqQ

    Hidden War, featuring activist Tim Ballard’s efforts against international child trafficking, serves as a direct follow-up to the 2023 film Sound of Freedom, which highlighted his initial undercover operations through Operation Underground Railroad (O.U.R.). While Sound of Freedom focused on Ballard’s work in Colombia and the broader fight against sex trafficking, Hidden War extends this narrative to operations in war-torn regions like Ukraine, Ecuador, and Mexico, documenting rescues amid global conflicts and exposing how displaced children become targets for exploitation.​

    The film’s release on November 14, 2025, comes amid reports of resistance from some cinema chains, echoing the grassroots momentum that propelled Sound of Freedom to over $250 million in worldwide box office success despite initial distribution challenges. Ballard, portrayed by Jim Caviezel in the earlier film, continues his advocacy, emphasizing the ongoing scale of the issue where more children are enslaved today than at any point in history.​

    Tim Ballard noted, “Films like Hidden War build on the awareness raised by Sound of Freedom to challenge institutional silence on child exploitation. Our goal remains delivering these stories to foster real change in communities affected by trafficking.”​

    To support wider access, audiences are encouraged to contact their local cinemas and request screenings of Hidden War for the November 14 debut.

    Key Details

    Theatrical release date: November 14, 2025

    Rating: PG-13

    About Hidden War
    Hidden War chronicles real-life anti-trafficking missions led by Tim Ballard, expanding on themes from Sound of Freedom to address global hotspots of child exploitation.

    Media inquiries: corporate@spanglishmovies.com

    Contact Information:
    Spanglish Movies LLC
    Valentina Saldivia
    787-525-4197
    Contact via Email
    www.spanglishmovies.com

    Read the full story here: https://www.pr.com/press-release/953319

    Press Release Distributed by PR.com

  • NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

    NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

    SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today reported that it has received approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (DRC).

    The proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is now cleared to proceed subject to filing of certain documents.

    “This is an important milestone in regulatory development of NV-387,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company.

    There is no drug available for the treatment of hMPXV infection that causes the MPox disease. A clinical trial of tecovirimat (TPOXX®, SIGA) failed to demonstrate any effectiveness over placebo, as per a NIH press release on August 15, 2024. Another drug, brincidofovir (TEMBEXA ®, EBS) entered into a clinical trial called “MOSA” with fanfare in January, 2025, with early topline results expected by the end of the quarter. The status of this clinical trial is not publicly known as of now.

    MPox Clade II has become endemic in the USA but it affects a limited population of Men-having-Sex-with-Men (MSM), because of transmission during sexual activity.

    Most recently, three new cases of MPox Clade I have been found in California in unconnected persons, with no travel to Africa; yet the MPXV viral genomes were found to be in the same cluster, suggesting that community spread of the MPXV Clade I is likely already occurring, according to the CDC (https://www.aha.org/news/headline/2025-10-29-cdc-says-3-cases-severe-mpox-california-may-be-linked-august-case).

    “NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases,” said Anil R. Diwan, Ph.D., adding “NV-387 is designed to mimic human cells to trap and destroy the virus. This single drug can target over 90-95% of human pathogenic viruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria.”

    The Company previously announced in May, 2025 that it has received an approval from the Ethics Committee CNES of the national regulatory agency in DRC that NV-387 can be considered for a Phase II clinical trial for the treatment of MPox. This approval was based on a summary package of information regarding NV-387 regulatory development until then. This Ethics Committee approval cleared the path for us to engage with the regulatory agency ACOREP and prepare the documentation required for their evaluation and approval as instructed by them.

    We have now completed submission of substantial required documentation in the draft forms as requested. We are now in the process of compiling all of this documentation together into the final form Clinical Trial Application, along with associated certifications and disclosures. These documents will be translated into French as required by the DRC. Both French and English sets of documents, certified to be accurately translated, will then be submitted to the ACOREP regulatory agency. The approval to start recruiting patients will then become effective.

    MPox disease, caused by the human MPox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the WHO African Region that includes the Democratic Republic of Congo (DRC), Uganda, and other countries. It led to the WHO declaring a Public Health Emergency of International Concern (“PHEIC”) on August 14, 2024 that was closed in September, 2025. However, the Mpox epidemic has continued to spread in the DRC, Uganda, and neighboring countries and the number of new weekly cases is still increasing in the WHO African Region. Therefore, the Africa CDC has maintained the status of the MPox pandemic as Public Health Emergency of Continental Security (“PHECS”).

    NV-387 was found to be highly effective in increasing survival in lethal animal models of influenza virus, surpassing existing drugs Tamiflu®, Rapivab® and Xofluza® by a large margin.

    NV-387 led to a complete cure of lethal RSV lung infection in an animal model study. There is no approved drug for RSV treatment.

    NV-387 was found to be highly effective in increasing survival in lethal animal models of Coronavirus infection (a stand-in model for SARS-CoV-2 infection), surpassing existing drug remdesivir by a large margin.

    NV-387 was also found to be highly effective against lethal lung infection by Measles virus in a humanized (hCD150+knock-in/IfnR-/-) mouse model.

    NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.

    In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.

    Escape of virus from tecovirimat can occur by a single point mutation in a viral protein called VP-37.

    Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu®), baloxavir (Xofluza®) for Influenza are readily escaped by viruses simply by introduction of small changes that viruses undergo when they are faced with these challenges in the field.

    In contrast, escape of virus from NV-387 is highly unlikely because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as “attachment receptor” in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.

    NV-387 is a host-mimetic drug that “looks like a cell” to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.

    Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.

    New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, and their limitations have become clearly evident during the COVID-19 pandemic.

    About NanoViricides

    NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

    The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

    Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

    NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

    The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

    This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

    The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

    Where stated with an ® , the name is a registered trademark, which belongs to the owner of the trademark name.

    FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

    Contact:
    NanoViricides, Inc.
    info@nanoviricides.com

    Public Relations Contact:
    ir@nanoviricides.com

    SOURCE: NanoViricides, Inc.

    View the original press release on ACCESS Newswire

  • XCF Global Strengthens Leadership to Accelerate Commercial Growth in Sustainable Aviation Fuel

    XCF Global Strengthens Leadership to Accelerate Commercial Growth in Sustainable Aviation Fuel

    • Seasoned energy-transition executive Chris Cooper appointed Chief Executive Officer and Board Director

    • Current XCF Board member, Wray Thorn, appointed Interim Board Chair to focus on strategy, growth, and capitalization

    • New Rise Renewables founder Randy Soule to work closely with Mr. Cooper and the XCF Board of Directors as Senior Operations Adviser

    HOUSTON, TEXAS / ACCESS Newswire / November 10, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a leader in advancing the decarbonization of the aviation industry through Sustainable Aviation Fuel (“SAF”), today announced key leadership appointments designed to optimize strategy, strengthen execution, and accelerate growth.

    Chris Cooper has joined the company as Chief Executive Officer (“CEO”) and Board Director, effective November 7, 2025. Mr. Cooper is a seasoned energy-transition executive who has served as President of Neste U.S. (North America), where he led strategy, operations, and stakeholder engagement for one of the world’s largest producers of renewable fuels, including SAF, and as Head of Renewables Trading at BGN, a leading energy and commodities trading company. Earlier in his career, he held senior leadership roles at Phillips 66 and Chevron, where he developed extensive expertise across downstream operations, renewable fuels integration, and global energy supply chains. Mr. Cooper succeeds Mihir Dange, who served as the Chief Executive Officer of XCF and XCF Global Capital, XCF’s predecessor, since November 2023.

    Chris Cooper, Chief Executive Officer of XCF Global, commented:
    “I’m honored to join XCF at this exciting inflection point for both aviation and renewable fuel. Global demand for SAF is accelerating, and XCF is well-positioned to lead through the rapid deployment of its modular facility design and international partnerships. Together with the Board and our partners, I’m committed to driving operational excellence, accelerating growth, and advancing XCF’s mission to decarbonize global air travel.”

    In conjunction with Mr. Cooper’s appointment, current XCF Board member Wray Thorn has been appointed Interim Board Chair, succeeding Mr. Dange as Board Chair, where he will focus on advancing the company’s strategic growth, capitalization, and governance initiatives.

    Wray Thorn, Interim Board Chair of XCF Global, added:
    “We are thrilled to welcome Chris to XCF at such a pivotal stage in the company’s evolution. His experience leading and scaling renewable fuel operations and his deep understanding of the global aviation fuel and SAF markets make him the right leader for XCF’s next phase of growth. The Board looks forward to working closely with Chris and the entire XCF management team as we continue to build the company into a leader in the renewable fuel industry and drive long-term value for our shareholders.

    “I’d also like to thank Mihir for his leadership of the company, as during his tenure as CEO and Board Chair, XCF made its public-market debut on Nasdaq and positioned itself as a key player in the SAF market.”

    Additionally, Randy Soule, founder of New Rise Renewables and the company’s largest shareholder, will work closely with Mr. Cooper as Senior Operations Adviser, helping to ensure operational excellence at XCF’s New Rise Reno facility. Mr. Soule brings deep technical, engineering, and operational expertise that will support XCF’s ongoing operations, expansion, and execution.

    Randy Soule, Founder of New Rise Renewables, added:
    “I am excited to welcome Chris to XCF as CEO and a member of the Board of Directors. His proven leadership in the renewable fuel industry, combined with the team’s extensive operational, technical, and engineering expertise, positions XCF to drive its next phase of growth and to enhance operational excellence.”

    Simon Oxley continues to serve as Chief Financial Officer, bringing more than 20 years of experience across the energy and finance sectors. Together, Mr. Cooper’s proven leadership in the renewable fuel industry and Mr. Oxley’s financial and strategic expertise in energy and capital markets position XCF to drive new growth opportunities, enhance shareholder value, and advance the company’s next stage of commercial growth and execution.

    About Chris Cooper
    Chris Cooper leverages more than 25 years of experience in the global energy industry. As President of Neste U.S. (North America), he oversaw regional leadership for renewable products, following his tenure as Vice President, Americas, Renewable Aviation. As Head of Renewables Trading at BGN, Mr. Cooper led global trading activities for renewable fuels, including SAF, renewable diesel, and biogenic feedstocks. Earlier in his career, he spent nearly two decades at Phillips 66 and Chevron, holding a range of leadership roles in commercial strategy, downstream operations, and business development. A professional pilot, Mr. Cooper brings a unique perspective on the aviation sector, combining operational depth with an international view of energy transition, renewable fuels, and infrastructure innovation.

    About Wray Thorn
    Wray Thorn is a Partner and Founder of Focus Impact Partners, LLC, and has been involved with XCF Global since late 2023. Mr. Thorn brings over three decades of experience as a CIO, investment leader, and lead director. He has participated in ~300 transactions, add-on acquisitions, realizations, corporate financings, fundraisings, and other principal transactions with aggregate consideration in excess of $32 billion. This includes over 40 direct private equity investments, nearly 100 direct venture investments, and more than 40 third-party managed fund investments. Mr. Thorn has also been a part of driving shareholder value creation and corporate growth as a member of boards and advisory boards of ~45 businesses and investment funds across multiple industries, including energy and transportation. He was previously a Managing Director and Chief Investment Officer – Private Investments at Two Sigma Investments, LP, where he architected and led the private equity, venture, and impact investment businesses.

    About XCF Global, Inc.

    XCF Global, Inc. is a pioneering sustainable aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF develops and operates state-of-the-art SAF production facilities engineered to the highest levels of compliance, reliability, and quality, and is building partnerships across the energy and transportation sectors to scale SAF globally. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX.

    For more information, visit: https://xcf.global.

    Contacts

    XCF Global:
    C/O Camarco
    XCFGlobal@camarco.co.uk

    Media:
    Camarco
    Andrew Archer | Rosie Driscoll | Violet Wilson
    XCFGlobal@camarco.co.uk

    Forward-Looking Statements

    This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses, including manufacturing and operating expenses and interest expenses, as a result of potential inflationary pressures, changes in interest rates and other factors; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to regain compliance with Nasdaq’s continued listing standards and thereafter continue to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing to fund its operations and business plan and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) the New Rise Reno production facility’s ability to produce renewable diesel in commercial quantities without interruption during the ongoing SAF ramp-up process; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (11) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (12) payment of fees, expenses and other costs related to the completion of the Business Combination and the New Rise acquisitions; (13) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (14) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (15) changes in applicable laws or regulations; (16) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (17) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (18) the availability of tax credits and other federal, state or local government support; (19) risks relating to XCF Global’s and New Rise’s key intellectual property rights, including the possible infringement of their intellectual property rights by third parties; (20) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (21) the effects of increased costs associated with operating as a public company; and (22) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global made or will make with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

    SOURCE: XCF Global, Inc.

    View the original press release on ACCESS Newswire

  • Moment of Clarity Publishes New Insight on How Deep TMS Therapy Advances Mental Health Treatment

    Moment of Clarity Publishes New Insight on How Deep TMS Therapy Advances Mental Health Treatment

    Oceanside, CA – November 13, 2025 – PRESSADVANTAGE –

    Moment of Clarity has published a new educational resource titled “How Deep TMS Therapy Works,” providing a comprehensive overview of transcranial magnetic stimulation (TMS) and its emerging role in modern mental health care. The publication, available on the Moment of Clarity website, explains the science behind Deep TMS therapy, its safety profile, and its effectiveness in treating depression, anxiety, and other treatment-resistant mental health conditions.

    The resource outlines how Deep TMS, an FDA-cleared therapy, uses magnetic pulses to stimulate neural activity in specific areas of the brain associated with emotional regulation and cognitive function. According to the Journal of Psychiatric Research, patients who received Deep TMS experienced significant improvement in depressive symptoms, with response rates exceeding 60% after a full course of treatment. These findings underscore the value of TMS for patients who have not achieved desired outcomes from medication or traditional psychotherapy alone.

    Moment of Clarity, Mental Health Treatment Center, Oceanside, California.

    Moment of Clarity’s new article explains that Deep TMS differs from conventional TMS by penetrating deeper cortical layers, allowing for broader and more effective stimulation. This technology is particularly beneficial for people struggling with treatment-resistant depression and obsessive-compulsive disorder (OCD). The resource cites data from Biological Psychiatry indicating that Deep TMS has demonstrated sustained improvement in mood and functional outcomes up to six months post-treatment, emphasizing its potential as a long-term therapeutic option.

    In line with national recommendations from the Substance Abuse and Mental Health Services Administration (SAMHSA), Moment of Clarity integrates Deep TMS therapy with cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and medication management as part of a personalized treatment framework. These combined approaches support both neurobiological and psychological recovery, enhancing resilience and emotional regulation over time.

    The resource also highlights Moment of Clarity’s outpatient model, which includes both in-person and virtual therapy options for mental health care. This flexible approach aligns with recent studies published in The Lancet Psychiatry, which found that teletherapy for depression and anxiety achieves comparable outcomes to in-person care when delivered through structured, evidence-based modalities like CBT and DBT. For patients in communities such as Rancho Carlsbad, Carlsbad Village, La Costa Meadows, and Aviara, this accessibility ensures continuity of care regardless of schedule or location.

    Medication management remains another key component of the treatment model discussed in the publication. The National Institute of Mental Health (NIMH) emphasizes that combining therapeutic interventions with closely monitored pharmacological support leads to higher rates of sustained recovery. The Moment of Clarity resource reiterates that proper dosage adjustments, medical supervision, and ongoing evaluation are essential for achieving consistent progress in mental health treatment.

    For patients in Aviara and Carlsbad Village who may be exploring Deep TMS or virtual therapy options, the publication provides research-backed information that clarifies what to expect before, during, and after treatment. The article details that Deep TMS sessions are typically conducted five times a week for several weeks, each lasting about 20 minutes, with no anesthesia or recovery time required. Most people can resume daily activities immediately, making it a practical choice for those managing work or family responsibilities alongside treatment.

    Moment of Clarity’s new educational resource also addresses misconceptions about TMS therapy, particularly regarding its safety and side effects. Clinical trials reported in the American Journal of Psychiatry indicate that fewer than 5% of patients discontinue treatment due to discomfort, with most side effects mild and transient, such as slight scalp sensitivity or a transient headache. These findings reinforce the therapy’s strong safety record and its growing acceptance among medical professionals as a viable alternative to medication-based treatment strategies.

    In Rancho Carlsbad and La Costa Meadows, where access to mental health resources continues to expand, more patients are turning to hybrid care models that integrate evidence-based therapies like CBT and medication management with advanced interventions such as Deep TMS. The publication emphasizes that this multi-dimensional approach supports long-term recovery by addressing both neurochemical and behavioral aspects of mental health conditions.

    Moment of Clarity’s release of “How Deep TMS Therapy Works” contributes to ongoing public education about the importance of innovation and transparency in mental health care. The article encourages readers to consult licensed clinicians for individualized evaluations and to consider how combining Deep TMS with therapeutic interventions may enhance treatment outcomes.

    People in Oceanside and nearby areas, including Rancho Carlsbad, Carlsbad Village, La Costa Meadows, and Aviara, can visit the Moment of Clarity Oceanside to explore outpatient and virtual therapy services, medication management programs, and advanced mental health treatment options.

    ###

    For more information about Moment of Clarity Oceanside, contact the company here:

    Moment of Clarity Oceanside
    Marie Mello
    (949) 288-2392
    marie@momentofclarity.com
    2215 Mesa Dr, Oceanside, CA 92054

  • Best Awning Company Introduces Wind-Resistant Retractable Awnings for Denver Properties

    Best Awning Company Introduces Wind-Resistant Retractable Awnings for Denver Properties

    Conifer, Colorado – November 14, 2025 – PRESSADVANTAGE –

    Best Awning Company has introduced a new line of wind-resistant retractable awnings designed specifically for Colorado’s challenging weather conditions, addressing increased demand for durable outdoor shade solutions across the Denver metropolitan area.

    The newly launched collection features reinforced frame construction and advanced fabric technology engineered to withstand wind speeds up to 35 miles per hour, a significant improvement over standard retractable awning systems. The products incorporate heavy-duty aluminum frames with enhanced bracket systems and specialized fabric tensioning mechanisms developed for Front Range weather patterns.

    Best Awning Company

    “Wind resistance has been the primary concern for Denver property owners considering retractable awnings,” said Tyler Coomes, Director of Operations at Best Awning Company. “These new systems address that challenge directly with engineering improvements that allow the awnings to remain deployed in conditions that would require standard models to be retracted.”

    The wind-resistant models join the company’s existing product line as part of a broader expansion of retractable awning options for both residential and commercial applications. The systems feature automatic wind sensors that retract the awnings when wind speeds exceed safe operating limits, preventing potential damage during sudden weather changes common to the Denver area.

    Best Awning Companys Retractable Denver Awnings now include models with reinforced lateral arm technology and upgraded mounting hardware designed to distribute wind load more effectively across the entire structure. The awnings are available in widths ranging from 8 to 40 feet, with projection distances up to 14 feet from the mounting surface.

    Testing conducted at the company’s Denver facility demonstrated the new systems’ ability to maintain structural integrity during sustained winds and gusts typical of Colorado spring and fall seasons. The awnings underwent stress testing simulating various weather scenarios, including rapid temperature fluctuations and exposure to hail impact.

    Installation of the wind-resistant models follows the same timeline as standard retractable awnings, with most projects completed within two to four weeks of design approval. The company’s installation teams have received specialized training on the new mounting requirements and structural specifications unique to the enhanced models.

    Commercial applications for the wind-resistant awnings include restaurant patios, retail storefronts, and outdoor event spaces where reliable shade coverage is essential for business operations. The systems allow businesses to maintain outdoor seating areas during variable weather conditions without frequent manual adjustments.

    The introduction of wind-resistant technology represents a response to feedback from property owners who previously avoided retractable awnings due to concerns about Colorado’s unpredictable weather. Market research conducted by the company indicated wind resistance as the top factor influencing purchasing decisions among Denver-area consumers.

    “Property owners want the flexibility of retractable shade without worrying about weather-related damage,” added Coomes. “These systems provide that peace of mind while maintaining the aesthetic appeal and functionality that make retractable awnings attractive.”

    Best Awning Company has been providing shade solutions to Denver area properties since 1979. The company specializes in retractable awnings, window awnings, metal awnings, pergola systems, and commercial installations, along with repair and fabric replacement services. Their product offerings include partnerships with manufacturers such as SunSetter and KE Awnings, providing access to materials and technology suited for Colorado’s climate conditions.

    ###

    For more information about Best Awning Company, contact the company here:

    Best Awning Company
    Tyler Coomes
    303-816-2303
    sales@myawnings.com
    11485 Old US Hwy 285 #120
    Conifer, CO 80433

  • Vanguard Online Marketing Empowers Local Growth with Proven SEO Strategies

    Vanguard Online Marketing Empowers Local Growth with Proven SEO Strategies

    PALMETTO BAY, FL – November 13, 2025 – PRESSADVANTAGE –

    Vanguard Online Marketing, a growing digital marketing firm, focuses on supporting digital success for small and mid-sized companies across South Florida, including Kendall.

    Over the years, Vanguard has worked with businesses to improve their online exposure, compete more effectively against local competitors, and create opportunities to turn search traffic into qualified leads.

    Founded by Edward Gelb, CEO, Vanguard Online Marketing combines a thorough understanding of search engine optimization (SEO) with data-driven methodologies and local knowledge customized for the Kendall market and the surrounding areas it serves. The firm’s strategy is to provide personalized solutions that boost online presence and provide demonstrable outcomes.

    “Our goal is to help businesses improve their search rankings and increase their potential for company growth by attracting relevant visitors and encouraging client engagement,” Gelb explains.

    Vanguard Online Marketing’s strategy starts with an in-depth analysis of a client’s market positioning, company goals, competitors, and existing digital performance. This full examination yields a tailored plan that includes on-page SEO, local citations, link development, content creation, and technical optimization. These efforts are meant to help establish an online presence that is aligned with search engine criteria, while noting that outcomes depend on many factors and are not guaranteed.

    Vanguard Online Marketing’s deep understanding of the Kendall community enables it to deliver campaigns that resonate with local consumer behavior. The strategy aims not only to improve search rankings but also to help build recognition and authority within respective business niches.

    The SEO marketing company works to improve its clients’ visibility in search results and aims to build a strong online presence. To further support growth, Vanguard Online Marketing offers a full digital marketing suite, complementing SEO efforts. It covers Google Business Profile optimization, social media management, pay-per-click (PPC) advertising, content marketing, reputation management, and comprehensive analytics with clear reporting. Each service aspect is intended to complement the SEO strategy, ensuring brand consistency and increasing customer confidence across numerous digital platforms.

    Vanguard serves clients across industries—including legal, home services, health and wellness, real estate, and retail—and focuses on improving search visibility, lead generation, and website performance. The company’s combination of strategic knowledge and specialized marketing tools has helped facilitate these successes. At the same time, clients are reminded that SEO is a process that is evolving and influenced by numerous variables in the digital ecosystem.

    In today’s digital environment, where authority and trustworthiness play key roles in search rankings, Vanguard Online Marketing employs data-driven SEO and local optimization practices to enhance brand identity and online credibility. This approach supports clients not only in improving their rankings on Google but also in improving user perception and conversion potential by establishing a cohesive brand presence across multiple platforms.

    Transparency is a core value for Vanguard Online Marketing. Business owners receive performance reports outlining keyword ranking progress, traffic analytics, conversion metrics, and SEO health indicators. Campaigns are continuously monitored and refined to adapt to shifting market conditions and ongoing search algorithm updates. The SEO marketing company maintains a focus on fostering sustainable growth rather than short-term gains.

    As search behavior changes and competition heats up, Kendall companies may turn to Vanguard Online Marketing for guidance in navigating the changing digital landscape. The company’s commitment to SEO tactics that adhere to industry standards and applicable regulations, demonstrate local market understanding, and produce quantifiable business results supports its role as an SEO marketing partner for businesses across Florida.

    For companies interested in exploring how Vanguard Online Marketing’s SEO strategies may support business growth, a free, no-obligation consultation is available. Interested parties can visit www.vanguardonlinemarketing.com or call (786) 373-1132 to schedule a consultation.

    About Vanguard Online Marketing
    Vanguard Online Marketing is a full-service digital marketing agency focused on SEO and online growth strategies, dedicated to helping businesses in South Florida increase visibility, leads, and revenue.

    ###

    For more information about Vanguard Online Marketing, contact the company here:

    Vanguard Online Marketing
    Samuel Gelb
    (786) 373-1132
    samuel@vanguardonlinemarketing.com
    17945 SW 97th Ave #418, Palmetto Bay, FL 33157

  • Webster Home Care Emphasizes How Personalized Support Helps Adults Thrive Safely in Their Own Homes

    Webster Home Care Emphasizes How Personalized Support Helps Adults Thrive Safely in Their Own Homes

    WESTBOROUGH, MA – November 12, 2025 – PRESSADVANTAGE –

    BSD HOME CARE MANAGEMENT LLC, operating as Webster Home Care, highlights the growing importance of person-centered home care services that enable adults to maintain independence while receiving professional support in familiar surroundings.

    As the aging population continues to expand and more families seek alternatives to institutional care, home care agencies are adapting their approaches to focus on preserving dignity, autonomy, and quality of life for clients. Webster Home Care addresses this need through comprehensive support programs that balance safety with independence, allowing adults to remain in their homes while receiving necessary assistance.

    “The foundation of effective home care lies in understanding that each individual has unique needs, preferences, and goals,” said Shmuel Septimus, a representative from BSD HOME CARE MANAGEMENT LLC. “Our approach centers on creating personalized care plans that respect the independence our clients value while ensuring they receive the support necessary for their well-being and safety.”

    The emphasis on person-centered care reflects broader shifts in the home health industry, where agencies increasingly recognize that successful outcomes depend on more than medical support alone. Factors such as maintaining social connections, preserving daily routines, and respecting individual preferences play crucial roles in overall health and happiness for adults receiving home care.

    Webster Home Care Westborough focuses on building trust with both clients and their families through transparent communication and consistent, reliable service delivery. This approach acknowledges that family members often experience significant stress when making care decisions for loved ones, and establishing confidence in care providers becomes essential for peace of mind.

    The agency’s services encompass various aspects of daily living support, from assistance with personal care and medication management to companionship and household tasks. By addressing multiple dimensions of client needs, the organization aims to create comprehensive support systems that adapt as individual requirements change over time.

    “Families tell us that knowing their loved ones can maintain their independence while having professional support available brings tremendous relief,” added Septimus. “We view ourselves as partners in helping adults navigate the challenges of aging or managing health conditions while preserving the lifestyle and routines that bring them comfort and joy.”

    The growing demand for home care services reflects demographic trends and changing preferences among older adults and their families. Research consistently shows that most seniors prefer to age in place when possible, and home care services make this option viable for many who might otherwise require institutional care.

    Webster Home Care Services operates from its location at 112 Turnpike Road in Westborough, Massachusetts, serving the local community with professional home health care services. The organization maintains a commitment to accessibility and responsiveness, operating Monday through Friday to address client needs and family inquiries.

    BSD HOME CARE MANAGEMENT LLC continues to evolve its service offerings in response to community needs and industry best practices. The company’s focus on person-centered care, family partnership, and maintaining client independence represents its core approach to supporting adults who wish to remain safely in their homes while receiving professional care assistance.

    ###

    For more information about BSD HOME CARE MANAGEMENT LLC, contact the company here:

    Webster Home Care
    Shmuel Septimus
    (508) 449-4064
    info@websterhc.com
    112 Turnpike Rd, Westborough, MA 01581

  • Moment of Clarity Publishes New Resource Detailing How Spravato Supports Bipolar Depression Treatment

    Moment of Clarity Publishes New Resource Detailing How Spravato Supports Bipolar Depression Treatment

    RESEDA, CA – November 13, 2025 – PRESSADVANTAGE –

    Moment of Clarity has published a new educational article titled “Spravato for Bipolar Depression Treatment“, providing an in-depth exploration of how esketamine therapy is being used to manage symptoms of treatment-resistant bipolar depression. The resource, available on the Moment of Clarity website, highlights recent clinical research, safety considerations, and the role of Spravato within modern evidence-based mental health treatment.

    According to the National Institute of Mental Health (NIMH), bipolar disorder affects approximately 4.4% of U.S. adults during their lifetime, and many patients experience limited success with traditional medications or therapy alone. Spravato, the FDA-approved nasal spray form of esketamine, represents a new treatment option for people whose depression symptoms persist despite standard antidepressant use. The Moment of Clarity publication draws from peer-reviewed studies and professional guidelines to clarify how this medication-assisted therapy supports long-term recovery and improved stability.

    Group Therapy Mental Health Treatment, Reseda, California. Moment of Clarity.

    Research cited in The American Journal of Psychiatry found that more than 50% of patients receiving esketamine treatment for bipolar depression experienced significant symptom reduction within the first four weeks of use. The resource explains that this rapid response rate distinguishes Spravato from traditional antidepressants, which often require several weeks to show measurable effects. However, the article also stresses that Spravato therapy should always be administered under strict medical supervision as part of a broader, integrated mental health treatment plan.

    Moment of Clarity’s resource outlines how Spravato can complement psychotherapeutic approaches such as cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), and group therapy for trauma survivors. Combining pharmacological and psychotherapeutic methods is supported by the Substance Abuse and Mental Health Services Administration (SAMHSA) as one of the most effective strategies for long-term mental health outcomes. The article further notes that medication management remains essential to ensure dosage accuracy, monitor progress, and prevent side effects.

    In communities such as Chatsworth South, West Hills, Tarzana Encino Estates, and Studio City Foothills, access to comprehensive mental health services is vital for people managing chronic depression and bipolar disorder. The resource highlights that outpatient and intensive outpatient (IOP) programs offer flexible treatment models that enable patients to balance work or school commitments with structured therapeutic support. These formats have been shown in studies published by the Psychiatric Services Journal to improve adherence and recovery rates for mood disorders.

    The publication also emphasizes how Moment of Clarity integrates medical innovation with compassionate care. By offering options such as Spravato therapy, transcranial magnetic stimulation (TMS), and traditional counseling, patients receive treatment tailored to both biological and psychological factors. Data from JAMA Psychiatry indicates that combining esketamine treatment with psychotherapy enhances overall emotional resilience and quality of life, particularly among people with co-occurring anxiety or trauma histories.

    Spravato’s mechanism of action—targeting the brain’s glutamate system—helps restore disrupted neuronal communication, which is often linked to depressive episodes. The resource explains that this approach differs from conventional antidepressants that primarily focus on serotonin and norepinephrine. Clinical trials show that patients receiving esketamine therapy under medical guidance often report improved mood regulation, reduced intrusive thoughts, and enhanced motivation to engage in treatment.

    For residents of Tarzana Encino Estates and Studio City Foothills, the new resource also highlights the growing demand for accessible, evidence-based mental health treatment centers. The article notes that Spravato is administered in controlled clinical settings, where patients are monitored for at least 2 hours after treatment. This level of oversight ensures safety and reinforces accountability throughout the therapeutic process.

    Moment of Clarity’s educational article additionally discusses how trauma-informed care models align with medication-assisted therapies like Spravato. For people with bipolar depression rooted in unresolved trauma, integrating group therapy for trauma survivors alongside medical interventions can help build coping skills and emotional awareness. According to The Journal of Traumatic Stress, trauma-focused group therapy participants demonstrate higher levels of sustained progress compared to those receiving individual treatment alone.

    The publication concludes by reaffirming the importance of providing accurate and transparent education about emerging treatments. As mental health continues to evolve through advances in neuroscience and psychology, resources like Moment of Clarity’s Spravato guide help demystify complex clinical information for patients and their families.

    Residents across Reseda and nearby communities, such as Chatsworth South, West Hills, Tarzana Encino Estates, and Studio City Foothills, can learn more about Spravato therapy and other mental health treatment options by visiting Moment of Clarity Reseda. The article provides a factual, research-informed overview to help patients make confident decisions about their care in collaboration with licensed mental health professionals.

    ###

    For more information about Moment of Clarity Reseda, contact the company here:

    Moment of Clarity Reseda
    Marie Mello
    (747) 337-3075
    marie@momentofclarity.com
    18617 Keswick St, Reseda, CA 91335